MedPath

CAR-T Therapy Demonstrates Significant Reduction in Multiple Myeloma Disease Burden

• Data from the CARTITUDE-4 clinical trial indicates that CAR-T therapy shows improved outcomes compared to standard of care for multiple myeloma patients. • Cerebrospinal fluid (CSF) analyses from patients treated with a novel therapy showed over 80% reduction in NAA levels from baseline, suggesting significant therapeutic impact. • Anixa Biosciences received clearance for a single-patient investigational new drug application to redose a patient in a clinical trial, allowing for extended evaluation.

CAR-T therapy is demonstrating promising results in reducing disease burden in multiple myeloma patients, according to data from the CARTITUDE-4 clinical trial. The trial compared outcomes of patients treated with CAR-T therapy to those receiving standard of care, revealing significant improvements in the CAR-T arm.

Impact on NAA Levels in CSF

In a separate study, cerebrospinal fluid (CSF) analyses from seven patients treated with an innovative therapeutic approach showed substantial reductions in N-acetylaspartate (NAA) levels. Specifically, NAA levels decreased by more than 80% from baseline in these patients. This reduction suggests a significant impact on disease activity within the central nervous system.

Anixa Biosciences' Redosing Strategy

Anixa Biosciences has obtained clearance for a single-patient investigational new drug (IND) application, enabling the redosing of a patient within a clinical trial. This redosing strategy allows for extended evaluation of the therapy's long-term effects and potential benefits in individual cases.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

CAR-T Therapy Shows Promise in Lenalidomide-Refractory Multiple Myeloma

CARTITUDE-4 trial results show promise for patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy, indicating a potential new treatment option.
Five-year follow-up data from the TRANSCEND-NHL-001 trial were discussed, providing insights into the long-term efficacy and safety of CAR-T cell therapy in lymphoma.

Advancements in Gene and Cell Therapies Target Diverse Diseases

Ultragenyx seeks accelerated FDA approval for UX111, a gene therapy for MPSIII, based on Phase 1/2/3 trial data.
Arbor Biotechnologies' CRISPR-based therapy ABO-101 receives clearance for US trial in Primary Hyperoxaluria Type 1.

FDA Sets PDUFA Date for Gene Therapy Targeting AADC Deficiency

The FDA has set an action date of April 29, 2025, for a Biologics License Application (BLA) for a gene therapy intended to treat Aromatic L-Amino Acid Decarboxylase (AADC) deficiency.
The gene therapy, already approved in the UK and European Union under the brand name Upstaza since 2022, showed promising results in clinical trials.

FDA Clears First IND for Circular RNA Therapy, RiboX

RiboX receives FDA clearance for its Investigational New Drug (IND) application, marking the first such clearance for a circular RNA therapy.
A study co-authored by a physician at the Cancer Center at Children's Hospital of Philadelphia was recently published in Blood, adding to the advancements in gene and cell therapies.

Liso-cel Demonstrates Significant Response in Relapsed/Refractory Marginal Zone Lymphoma

Bristol Myers Squibb's liso-cel achieved a statistically significant and clinically meaningful overall response rate in patients with relapsed or refractory marginal zone lymphoma.
The Phase 2 trial results highlight the potential of liso-cel as an effective treatment option for this challenging patient population.

Gene Therapy for Parkinson's Shows Promise in Phase 2 Trial

A phase 2 trial of a gene therapy for Parkinson's disease demonstrated an average improvement of 18 points in UPDRS Part 3 "off" medication score at 26 weeks post-treatment.
The data comes from a phase 2 substudy (NCT03999801) that treated the fellow eyes of patients who had previously been treated with ABBV-RGX-314.

Benitec BioPharma's Gene Therapy Shows Promising Results in Oculopharyngeal Muscular Dystrophy Trial

Benitec BioPharma reports a 35% reduction in total score on the Sydney Swallow Questionnaire in the first patient treated with their gene therapy for oculopharyngeal muscular dystrophy (OPMD).
Therapeutic RNA editing has been clinically demonstrated in humans for the first time, according to the company's press release.

Cell Therapy Shows Promise in Progressive Multiple Sclerosis

A cell therapy is under development for progressive multiple sclerosis (MS) patients with ongoing inflammatory tissue injury and who are HLA-DRB1*15:01 positive.
GT201, a novel therapy, previously received IND clearance from China’s Center for Drug Evaluation in July 2023, marking a significant regulatory milestone.

Galapagos' ATALANTA-1 Clinical Trial for Hemophilia A to Expand to the US Following IND Clearance

Galapagos' ATALANTA-1 phase 1/2 clinical trial (NCT06561425) for hemophilia A is set to expand to the United States after receiving IND clearance.
The ATALANTA-1 trial is already ongoing in Europe and will now include US sites to further evaluate the safety and efficacy of their hemophilia A treatment.

CAR-T Therapies Gain Ground in China and Beyond: Regulatory Approvals and Clinical Advancements

Legend Biotech's Carvykti (cilta-cel) receives approval in China for relapsed or refractory multiple myeloma after multiple lines of prior therapy.
JW Therapeutics' Carteyva (relma-cel) gains approval in China for treating relapsed or refractory mantle cell lymphoma in adult patients.

Reference News

[1]
CGTLive®'s Weekly Rewind – October 4, 2024
cgtlive.com · Oct 5, 2024

CGTLive’s Weekly Rewind highlights 5 gene and cell therapy advances: CARTITUDE-4 trial outcomes, Ocugen’s phase 3 gene t...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy